A simple method which uses lOO!J.l serum has been developed to measure the binding of somatomedin B (5MB) to protein in serum from normal children, adults, and patients with growth hormone deficiency. 12fi1-labelled 5MB was used as binding ligand. The correlation between the binding of label by the proposed procedure and by an immunoelectrophoretic technique was acceptable (r=O· 73; p <0,02). The mean percentage oflabel bound to protein in serum from patients with deficiencies of growth hormone or other trophic hormones was significantly (p <0'001) lower than that for controls. The physicochemical characteristics of a specific binding-protein suggested that a protein with low capacity (160 pmol.l) and low K, (4' 37 x lOBI/mol was present in serum, in addition to a high concentration of alpha globulints) which also bound 12°1 5MB.
Highly purified (98 %) human somatomedin B for iodination was purchased from Kabi Vitrum Ltd, Ealing, London. Anti-human 5MB antiserum (rabbit) was purchased from the same source.
Three separate batches of purified 5MB studied over three years, when labelled with 125 1, were shown in a double-antibody technique to bind specifically to the antiserum. Binding varied from 15% to 20%. The average intrinsic association constant (K a ) calculated from standard curves according to the procedure of Pinckard The somatomedins (SM) are growth-hormonedependent peptides of molecular weight 5 to 7 x 10 3 daltons.! Somatomedin A insulin growth factors (IGF-l and IGF-2) are insulin-like and members of a family of factors present in serum that modulate the growth of responsive cells.2-4 Somatomedin B, on the other hand, is not insulin-like, questionably growth hormone-dependent, and does not have the same amino-acid composition as the insulin-like somatornedins." The insulin-like somatomedins are transported in peripheral blood bound to specific gamma globulin carrier proteins (CP) of molecular weight >60 x 10 3 daltons," 7 Animal models" Bhave suggested that the synthesis of CP is regulated by growth hormone and thyroid hormones with some modulation by the glucorticoids.
The present study describes an attempt to test the hypothesis that, in children with hypopituitarism, lack of growth hormone may lead to a reduction in the binding of 5MB to proteins in their blood. For this purpose, a simple method has been developed that uses 5MB available from commercial sources. This was labelled with 1251.
IODINATION OF 5MB
The lactoperoxidase method'! was previously used for iodination of 5MB, followed by two-stage G-25 and G-75 sephadex gel chromatography to remove iodinated lactoperoxidase and damaged 5MB. This method has proved tedious and has led to low specific activities.P In the present study, the iodination technique of Salacinski et aU 3 was used followed by separation of the 120 1 labelled 5MB from 12°1 on columns of Sephadex G-25.
Specific activities ranged from 172 to 262 lLCi/lLg. Non-lipaemic (preprandial) serum was obtained from blood collected by venepuncture between 1000 and 1400 from normal volunteers and hospitalised children and stored at -20 DC. None of the controls had clinical or biochemical evidence of hypopituitarism.
ASSAY OF 5MB BINDING IN SERUM
Duplicate serum samples (100 lLl) were diluted 1 in 4 with buffer (300 ul), An aliquot (200 lLI) was then serially diluted with further 200 lLl volumes of buffer to a final dilution of 1/128. The dilutions were therefore equivalent to 50 lLl to 1·56 lLl of undiluted serum in 200 lLl buffer. Radiolabelled 5MB was diluted in the same buffer to yield approximately 10 x 10 3 cpm/50 lLI, and an aliquot (50 lLI) was added to each tube. Duplicate tubes containing buffer and label only were included with each batch of serum as a measure of non-specific binding of label. All tubes were incubated for 2 hours at 4DC, after which 250 lLl of cold (4DC) saturated ammonium sulphate was added dropwise with mixing. The tubes were centrifuged (2500 g) for 30 minutes at 4DC, the supernatant was decanted, and the tubes were drained for 30 minutes on a pad of absorbant. The precipitates were counted in a welltype gamma counter with an efficiency for 125 1 of 80 %. The proportion of total counts that was bound (B) to each precipitate after subtraction of nonspecific bound label was then calculated as a percentage of the total counts (T) net background added to each tube. Non-specific binding of label to the tubes was small (2-3 %).
Experimental methods

INCUBATION TIME, BINDING STUDIES, AND PRECISION
Incubation time was varied from 2 to 18 hours, but the percentage of label bound did not change significantly after 2 hours. 12°1 5MB binding curves were constructed from serum obtained from six normal children and four adults. The mean (± 1 SD) binding was 40·4±4· 5 % in the presence of 50 lLl serum, falling progressively Rudd, Rayner, Stafford, and Halliday to 6·1 ± 3·1% with 1·56 lLl serum in the assay. The coefficient of variation approached a minimum when 12·5 to 50 lLl of serum was used (CY 13·4 to 11. 1 %). Further evaluation of method precision was carried out using the equivalent of 12·5 lLl serum in the assay as the reference point. Two control pools of serum were analysed over six months using five different labels. The interassay coefficient of variation with 12·5 lLl serum in the assay was 13 % with a mean binding of 15·7 ± 2 %. The intra-assay coefficient of variation using the same volume of serum, based on 19 pairs of samples from children with growth disorders, was 5·8 % with a mean binding of 15·0 ± 0·9%.
Binding capacity studies were carried out after removal of endogenous 5MB with charcoal. Pooled sera from normal children were diluted 1 : 16 with buffer containing 10 mg/rnl norit A charcoal and mixed for 1 hour.
After centrifuging, aliquots (200 !J.I) of supernatant equivalent to 12·5 !J.I serum were incubated with increasing doses of 125 1 5MB and unlabelled 5MB standard (total dose 2·5 to 366 fmol). Separation of free from bound label was as described in the method. A Scatchard plot of the data was constructed after correction for non-specific binding. The calculated capacity of a specific binding protein was 160 prnol/l with a K a of 4·37 x 1OBI/mol.The results suggested that a low capacity protein of low K a 'was present. The experiment was repeated with 50 !J.I of serum in the assay, which gave a similar K, of 5·1 x lOB l/rnol. There was a high concentration of secondary (unsaturatable) binding sites present in both experiments. SPECIFICITY An indirect method was used to assess specificity. 10 !J.I of serum from normal children was preincubated for I hour at room temperature with approximately 50 times more 125 1 5MB than used in the proposed method (circa 500 x 10 3 cpm/lO !J.I). 10!J.I of the mixture (5!J.I serum) was then separated in a one-dimensional immunoelectrophoresis system containing 3 % normal whole human antiserum. After washing and dehydration, the plates were auto-radiographed on Rx (Medical) Fuji x-ray film for five days. A single labelled precipitin line was seen, and the excess 125 1 5MB ran ahead of this line. Trailing of label was noted with sera that had been stored deep frozen more than three months. Analysis by the proposed method (12·5!J.I serum in the assay) of three separate serum samples which had been stored deep frozen for more than three months also showed a reduction in binding (mean, before storage 19·7%, after storage 14·9%).
The locus of the 125 1 5MB binding was further investigated by two-dimensional crossed immunoelectrophoresis.
Two separate experiments were carried out. In the first, labelled 5MB was added to normal serum, the serum was electrophoresed and the plate washed to remove 125 1 5MB weakly bound to the serum proteins. In the second, the serum proteins were separated by electrophoresis and the plate was then immersed in buffer containing 125 1 5MB. The first washed plate showed binding of 125 1 SM to an 1X 1 -globulin with traces of label bound to the albumin peak. In sharp contrast, the plate immersed in buffered label showed significant binding of 125 1 5MB to two 1X 1 -globulins, four proteins in the 1X2/~1 region, and some binding to the albumin peak ( Fig. 1 ). There was evidence from immunoelectrophoretic studies (Dr J R Bradwell) that one of the 1X 1 globulins which bound the label was lXI-antitrypsin, but this remains to be confirmed.
A correlation was established between the percentage of label bound by 12· 5 !Jol serum in the proposed method and that calculated from data obtained by the one-dimensional immunoelectrophoretic technique. In this experiment, 10 serum samples plus two controls were studied.
The mean percentage of label was calculated from replicate analyses of the controls (% Be) by the proposed method and used as the reference point. The area at half peak height of the precipitin lines for the samples (As) was then expressed as a fraction of that for the controls (A e ) and the percentage of label bound to the samples (% B s ) was calculated from:
x % Be. The correlation (r) was 0·733 (p>0·02) and the linear regression equation was of the form y (%B by immunoelectrophoresis)=0·805x+2·525 The range studied (proposed method) was 12·6-29·6%. 1"uI senrnl Fifteen patients aged 2i to 18 years with varying degrees of growth hormone deficiency were studied (Table) . Some of the patients had other trophic hormone deficiencies as documented in the Table. Four of the children had low thyroxine concentrations (patients 6, 8, 9, and 15) due to secondary TSH deficiency. These patients were receiving thyroxine therapy (100-150 !Jog/day) at the time of investigation. Figure 2 compares the percentage of label bound Sex
Results
Weigh'
BA. for the first nine patients listed in the Table over the whole dilution range with that of 10 performed on samples stored deep frozen for less than three months. Figure 3 illustrates the mean binding (± 2 SD) of 16 normal controls when compared with the 15 patients; the point on the dilution curve where intra-assay coefficient of variation was minimal occurred when 12·5 III serum were used in the assay. Three of 15 (20%) of the growthhormone-deficient patients had 125 1 5MB binding which lay outside -2 SD of the mean for the controls. The Student's t test showed that there was a highly significant difference (p <0·001) between the. mean 12°1 5MB binding for the patients (18·8 ± 3·2 %) when compared with that for the controls (22·9 ± 3·6 %). To an approximation, taking the highest specific activity of the labels used as 262 IlCi/llg, a molecular weight for 5MB as 5·5 x 10 3 da1tons, and a 1:1 binding of label to the carrier protein, the mean concentration of labelled 5MB associated with unoccupied binding sites with 12·5 III of serum in the assay for the 16 normal controls was 59·6 pmol/I. In contrast, the mean binding for all 15 of the growth-hormone-deficient children was 48·9 pmol/l.
Discussion
The presence of high-molecular-weight globulins in human serum which bind the somatomedins is established," 7 14 The present studies have shown that the mean binding of 5MB to serum proteins was significantly lower for the patients when compared with controls, and that approximately 20 % of the growth-hormone-deficient children had reduced binding for 12°1 5MB. The method used did not take into account endogenous protein-bound 5MB. This may not, however, be of importance in view of the observations of Yalow et al. 14 that the total 5MB content present in fractions from plasma is largely dissociated from the specific binding protein. Further, the earlier report-'' that the total concentration of 5MB in the serum of children with growth-hormone deficiency is similar to that of normals suggests that the production of 5MB is normal in some patients with growth-hormone deficiency, whereas the synthesis of proteins which bind 5MB can be reduced. The cause of this reduced binding is speculative but may be directly related to the absence of growth hormone which is necessary for protein synthesis.
The investigations documented have further shown that the binding capacity of a specific binding protein is low (160 pmol/l), Taking the mean concentration of total 5MB in the serum of normal children-" as 1·3 fJ.mol/l, then the percentage of total 5MB which is bound to the specific carrier protein is only 0·012 %. The demonstration of heterogeneous binding 0[1 25 1 5MB by both Scatchard plots and two-dimensional immunoelectrophoresis would support the view that most of the 5MB circulating in serum is bound to rl. 1 / rl. 2 globulin(s) of high capacity but low affinity rather than to a single specific carrier protein. Alternatively, the heterogeneity of binding may be related to the presence of 5MB-like fragments in the preparation. Four structurally similar peptides have been demonstrated in some samples of 5MB. 5 The low affinity of these rl. 1 / rl. 2 globulins for 125 1 5MB is illustrated by the ease with which dissociation of label occurs during the immunoelectrophoretic and washing steps.
The correlation between the percentage of label bound by the proposed method and that by the immunoelectrophoretic procedure suggests that the simple precipitation technique is detecting a similar species of binding protein. Albeit, the bias towards higher 125 1 SM binding by precipitation with ammonium sulphate implies secondary binding to other globulins or binding to aggregated protein of a higher molecular weight. Fryklund et a/. 15 have reported the phenomenon of cold aggregation of 5MB-CP, the product of which elutes on Sephadex G-200 with a molecular weight> 100 x 10 3 daItons.
A carrier protein that binds only 40 % of labelled 5MB compared with 95% reported for a carrier protein that binds IGF-l,6 casts doubt on its physiological significance. It may be that unbound 5MB is more important. The absence of insulin-like activity and limited growth-promoting properties of non-protein-bound 5MB, however, separate it from the other serum growth factors. One brief report-" suggests that 5MB may have a protease inhibitory effect on trypsin.
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